- Argentina
- Finland
- Japan
- Senegal
- Asia Pacific
- France
- Korea
- Slovakia
- Australia
- Germany
- Malaysia/Singapore
- South Africa
- Austria
- Greece
- Mexico
- Spain
- Belgium
- Hong Kong
- Netherlands
- Sweden
- Brazil
- Hungary
- New Zealand
- Switzerland
- Canada
- India
- Norway
- Taiwan
- China
- Indonesia
- Pakistan
- Thailand
- Colombia
- Ireland
- Philippines
- Turkey
- Czech Republic
- Israel
- Poland
- United Kingdom
- Denmark
- Italy
- Portugal
- Venezuela
- All social media
January 27, 2012
— U.S. Food And Drug Administration Approves Pfizer’s INLYTA® (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1024677&newsId=20120127005774&newsLang=en
January 27, 2012
— Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph+ Chronic Myeloid Leukemia
http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1024677&newsId=20120127005383&newsLang=en
http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&ndmConfigId=1024677&newsId=20120126005694&newsLang=en
Popular Downloads
Pfizer Quarterly Corporate Performance – Fourth Quarter 2011
- Audio Webcast – Tuesday, January 31, 2012 – 10 AM E.D.T.
- Press Release – Fourth Quarter 2011
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Health Care Professionals
- Privacy Policy
Copyright © 2002–2012 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.